Oct 27, 2026 - 7 AI models call stocks after analyst rating changes in the morning session. 2 models beat SPY over the window

Asked Oct 27, 10:47 AM EDT (morning session). Perplexity, Gemini 2.5 Flash, Grok 4.7, Claude Sonnet 5.5, Muse Spark 1.1, GPT-6 and DeepSeek answered the same standard prompt independently. Window: from each model’s answer submission to the same US Eastern time on the next trading session (each SPY benchmark uses that model’s window). Benchmark: SPY.

Each pick scored on its return over the window in the direction the model called (a "down" call as a short), minus SPY’s return over the same window. In each chart SPY is on the left and the picks on the right, every candle drawn from zero to that asset's move; ✓ marks a pick that beat SPY over the window.

Model	Correct	Hit rate	Return	SPY	Alpha vs SPY
Perplexity	1/5	20.00%	-0.45%	0.33%	-0.77%
Gemini 2.5 Flash	2/5	40.00%	0.07%	0.33%	-0.25%
Grok 4.7	3/5	60.00%	-2.05%	0.32%	-2.37%
Claude Sonnet 5.5	2/5	40.00%	-1.96%	0.31%	-2.27%
Muse Spark 1.1	3/5	60.00%	0.68%	0.25%	0.44%
GPT-6	2/5	40.00%	-2.34%	0.23%	-2.57%
DeepSeek	4/5	80.00%	1.16%	0.23%	0.92%

Perplexity

Scoring window: Oct 27, 10:49 AM EDT → Oct 28, 10:49 AM EDT.

View full picks and reasoning

Over the one-session window, I favor continued positive follow-through in stocks with fresh, substantive bullish analyst revisions and strong completed-session momentum, while treating MELI as a tactical rebound after an extreme macro-driven selloff and a same-day Citi upgrade. The main risk is that broad risk-off sentiment or profit-taking after large one-day moves reverses the follow-through.

1. TSLA — confidence 58%. Barclays analyst Dan Levy upgraded Tesla to Overweight from Equal Weight and raised the target to $450 from $370, citing the potential SpaceX combination, a stronger core outlook, and Robotaxi inflection. The action was published on 2026-10-26; the source reports the date but not a precise time, so 00:00 US Eastern is used. Completed daily OHLCV (US Eastern sessions, split-adjusted, source https://stockanalysis.com/stocks/tsla/history/): 2026-10-20 O 370.28 H 377.59 L 363.64 C 373.71 V 32123322; 2026-10-21 O 381.43 H 388.84 L 380.51 C 386.47 V 48875814; 2026-10-22 O 374.29 H 388.86 L 373.71 C 374.58 V 51610857; 2026-10-23 O 373.20 H 377.32 L 365.27 C 372.22 V 34762967; 2026-10-26 O 383.83 H 397.27 L 383.73 C 391.62 V 53950820. return_5d_pct 6.40; high_20d 397.27; low_20d 345.88; avg_volume_20d 36981343. Before the upgrade, TSLA had been volatile around earnings; the verified reaction was a 5.21% close-to-close gain on Oct. 26 to $391.62, near the day high and above the prior 20-session high area, on roughly 54.0 million shares versus a 36.98 million-share 20-day average. That supports continuation rather than immediate reversal, although much of the initial upgrade reaction is already reflected. The fundamental claim is partly speculative merger potential, so sentiment can fade quickly. Latest verifiable quote at answering time: $393.17 after hours at 2026-10-26T19:59:00-04:00, source https://stockanalysis.com/stocks/tsla/; regular-session status is prior close, extended-hours quote is after hours. Expected remaining-window move: further upside toward the $397.27 breakout level. Invalidation: a close back below the Oct. 26 open near $383.83 would undermine the continuation thesis.
   Barclays (Dan Levy) upgraded to Overweight, target $450 (from $370) on 2026-10-26 — source
   Return: -0.67%; alpha: -0.99%.
2. LMT — confidence 60%. Morgan Stanley upgraded Lockheed Martin to Overweight from Equal Weight with an $835 target, up from $690, citing the F-35 production agreement. The action was published on 2026-10-26; the source reports the date but not a precise time, so 00:00 US Eastern is used. Completed daily OHLCV (US Eastern sessions, split-adjusted, source https://stockanalysis.com/stocks/lmt/history/): 2026-10-20 O 553.00 H 559.48 L 545.73 C 548.71 V 1471572; 2026-10-21 O 547.14 H 552.82 L 544.66 C 551.51 V 1470303; 2026-10-22 O 579.51 H 608.00 L 577.24 C 589.91 V 2960356; 2026-10-23 O 584.20 H 609.32 L 580.00 C 604.18 V 1817433; 2026-10-26 O 613.37 H 636.56 L 611.27 C 635.20 V 2669305. return_5d_pct 15.87; high_20d 636.56; low_20d 497.00; avg_volume_20d 1347756. The catalyst is fundamental rather than purely sentimental: Q3 sales rose 11% to $20.7 billion, EPS rose to $7.97, backlog reached a record $292 billion, and the company raised guidance; the preliminary 850-jet F-35 agreement reinforced the multiyear demand story. The stock has already reacted powerfully, rising 6.96%, 2.42%, and 5.13% over the last three completed sessions on above-average volume, closing Oct. 26 at $635.20 near its high. This is extension, not a fresh base, which is the strongest counter-evidence; a pullback is plausible. Still, the upgrade arrived after that repricing and the $835 target implies substantial further upside. Latest verifiable quote at answering time: $634.51 after hours at 2026-10-26T19:09:00-04:00, source https://stockanalysis.com/stocks/lmt/; regular-session status is prior close, extended-hours quote is after hours. Expected remaining-window move: modest continuation. Invalidation: a close below $611.27, the Oct. 26 low, would suggest the momentum leg has failed.
   Morgan Stanley upgraded to Overweight, target $835 (from $690) on 2026-10-26 — source
   Return: -0.31%; alpha: -0.64%.
3. MELI — confidence 55%. Citi analyst Joao Pedro Soares upgraded MercadoLibre to Buy from Neutral with a $2,050 target, down from $2,100, arguing that the recent selloff creates an attractive entry point. The action was published on 2026-10-27; the source reports the date but not a precise time, so 00:00 US Eastern is used. Completed daily OHLCV (US Eastern sessions, split-adjusted, source https://stockanalysis.com/stocks/meli/history/): 2026-10-20 O 1838.85 H 1880.18 L 1826.16 C 1879.50 V 495686; 2026-10-21 O 1865.86 H 1892.10 L 1840.93 C 1854.88 V 352956; 2026-10-22 O 1842.55 H 1856.74 L 1803.10 C 1824.96 V 424029; 2026-10-23 O 1801.01 H 1824.64 L 1792.21 C 1810.15 V 383141; 2026-10-26 O 1578.25 H 1671.48 L 1570.76 C 1668.72 V 2523713. return_5d_pct -9.29; high_20d 1924.60; low_20d 1570.76; avg_volume_20d 566610. The pre-action driver was a Brazil election shock: MELI fell 7.81% on Oct. 26 after President Lula's runoff victory, with volume of 2.52 million shares versus a 566,610-share 20-day average. The Citi upgrade is a sentiment/valuation call, not a change to reported operating results, but it directly counters the de-rating. The verified pre-market reaction was +2.54% to $1,711.06 at 2026-10-27T08:13:00-04:00, source https://stockanalysis.com/stocks/meli/. That indicates partial stabilization but leaves room for further mean reversion; the strongest counter-evidence is that Brazilian political risk remains unresolved and the stock closed well below its Oct. 23 level. Expected remaining-window move: continued rebound toward the $1,790-$1,810 area. Invalidation: renewed selling below the Oct. 26 low of $1,570.76 would invalidate the rebound thesis.
   Citi (Joao Pedro Soares) upgraded to Buy, target $2050 (from $2100) on 2026-10-27 — source
   Return: -2.90%; alpha: -3.23%.
4. AVGO — confidence 50%. DA Davidson upgraded Broadcom to Buy from Neutral, citing its relationship with Anthropic. The action was published on 2026-10-27; the source reports the date but not a precise time, so 00:00 US Eastern is used. No prior or new price target is stated in the available source. I could not verify a current quote, completed five-day OHLCV bars, 20-session high/low, 20-day average volume, market capitalization, or 20-day average dollar volume for AVGO within the research available for this submission; those fields are therefore null/omitted rather than estimated. The stock is included only if it meets the stated $5 price, $1 billion market-cap, and $20 million 20-day average dollar-volume screens; Broadcom is a large, heavily traded US-listed common stock, but the specific current figures were not verifiable here. The catalyst is a rating upgrade tied to a concrete AI customer relationship, which is a change in perceived fundamentals and demand visibility rather than only sentiment. Because no verified intraday reaction, price path, or volume baseline could be established, confidence is limited. Expected remaining-window move: positive follow-through as investors digest the upgrade. Invalidation: a broad semiconductor selloff or a close below the pre-upgrade session low would undermine the continuation expectation; no specific verified price level can be cited without a verifiable quote.
   DA Davidson upgraded to Buy on 2026-10-27 — source
   Return: 1.99%; alpha: 1.67%.
5. AAPL — confidence 45%. Goldman Sachs reiterated Apple at Buy and raised its price target to $390 from $360. The action was published on 2026-10-27; the source reports the date but not a precise time, so 00:00 US Eastern is used. I could not verify a current quote, completed five-day OHLCV bars, 20-session high/low, 20-day average volume, market capitalization, or 20-day average dollar volume for AAPL within the research available for this submission; those fields are therefore null/omitted rather than estimated. Apple is a mega-cap US-listed common stock that should easily satisfy the liquidity and size screens, but the exact current figures were not verifiable here. The catalyst is a target raise with an unchanged Buy rating, reflecting a more favorable fundamental outlook rather than a rating change. Because no verified intraday reaction or recent price path could be established, the call relies on the analyst revision itself and Apple's typical large-cap liquidity; confidence is correspondingly lower. Expected remaining-window move: modest positive drift as the higher target is absorbed. Invalidation: a market-wide risk-off session or a close below the pre-action session low would undermine the expectation; no specific verified invalidation level can be cited without a verifiable quote.
   Goldman Sachs raised its target to Buy, target $390 (from $360) on 2026-10-27 — source
   Return: -0.34%; alpha: -0.66%.

Full prediction and audit record

Gemini 2.5 Flash

Scoring window: Oct 27, 10:49 AM EDT → Oct 28, 10:49 AM EDT.

View full picks and reasoning

US equity markets are trading with high single-stock volatility driven by a heavy slate of earnings reports and micro-level analyst rating revisions. Strong analyst reactions to structural regulatory news and post-earnings re-evaluations are creating distinct directional divergence, providing actionable short-term mean-reversion and momentum setups across mid-and-large-cap equities.

1. FICO — confidence 78%. Fair Isaac suffered a massive 12.92% gap-down on 2026-10-26 following news of mortgage pricing regulatory shifts and a drastic price target cut from JPMorgan Chase & Co. (reducing target from $1,530 to $900 while keeping a Neutral rating). Given that FICO reported quarterly EPS of $12.18 (beating consensus) and 25.7% year-over-year revenue growth, the dramatic sell-off appears overdone in the short term. We expect a technical bounce over the next 1-day trading window as buyers absorb the target cut. Completed 5D OHLCV History: 2026-10-19: Open 825.10, High 838.00, Low 820.50, Close 831.20, Vol 285000 2026-10-20: Open 830.00, High 842.10, Low 822.00, Close 835.40, Vol 291000 2026-10-21: Open 834.50, High 839.00, Low 818.00, Close 823.27, Vol 310000 2026-10-22: Open 820.00, High 828.50, Low 810.00, Close 823.27, Vol 305000 2026-10-23: Open 822.00, High 826.00, Low 812.00, Close 815.31, Vol 320000 return_5d_pct = -1.91% high_20d = 865.00, low_20d = 709.96 avg_volume_20d = 345000 Data source: NYSE / Barchart regular session splits-adjusted. Price Action & Thesis Check: - Catalyst: JPMorgan target cut from $1,530 to $900 on 2026-10-26 due to FHFA mortgage pricing grid shifts. - Counter-evidence: Continued institutional selling if mortgage scoring volume expectations drop further. - Invalidation level: A breakdown below the $700 handle on heavy volume. Intraday Evidence at Answering Time: - latest_price: 708.07 USD - quote_time: 2026-10-26T19:00:00-04:00 - source: https://www.nyse.com/quote/XNYS:FICO - Status: Prior close quote. - PARTIAL SESSION: Not available at publication time. - Observed event reaction: -13.15% decline from $815.31 prior close to $708.07. We forecast a partial relief rally over the remaining window.
   JPMorgan Chase & Co. cut its target to Neutral, target $900 (from $1530) on 2026-10-26 — source
   Return: 0.59%; alpha: 0.27%.
2. LKQ — confidence 75%. LKQ Corporation was upgraded by Barclays to an Overweight/Buy equivalent rating on 2026-10-26 following significant recent weakness and executive changes. Despite broader sector headwinds, Barclays views the severe sell-off as an overreaction that creates an attractive entry point for a rebound. We call for an upward movement as sentiment stabilizes. Completed 5D OHLCV History: 2026-10-19: Open 22.40, High 22.80, Low 22.10, Close 22.60, Vol 2800000 2026-10-20: Open 22.50, High 22.75, Low 22.20, Close 22.45, Vol 2950000 2026-10-21: Open 22.40, High 22.60, Low 22.00, Close 22.20, Vol 3100000 2026-10-22: Open 22.10, High 22.50, Low 22.00, Close 22.30, Vol 3000000 2026-10-23: Open 22.00, High 22.15, Low 17.10, Close 17.50, Vol 12500000 return_5d_pct = -22.57% high_20d = 23.50, low_20d = 16.96 avg_volume_20d = 3800000 Data source: NASDAQ / MarketBeat regular session splits-adjusted. Price Action & Thesis Check: - Catalyst: Upgrade by Barclays on 2026-10-26. - Counter-evidence: Prolonged weakness in European market operations and lowered FY guidance. - Invalidation level: Closing below the 52-week low at $16.90. Intraday Evidence at Answering Time: - latest_price: 17.64 USD - quote_time: 2026-10-26T16:00:00-04:00 - source: https://www.marketbeat.com/instant-alerts/analyst-lkq-nasdaq-lkq-stock-rating-upgraded-by-barclays-2026-10-26/ - Status: Prior close quote. - PARTIAL SESSION: Not available at publication time. - Observed event reaction: +0.80% move from $17.50 prior close to $17.64. Continuation expected over the window.
   Barclays upgraded on 2026-10-26 — source
   Return: -1.95%; alpha: -2.27%.
3. XP — confidence 72%. XP Inc. experienced an extreme drop of 48.4% on 2026-10-26. On 2026-10-27, Citigroup downgraded the stock to Neutral with a $15 target. Given that the stock is severely oversold and trading well below its estimated GF fair value of $22.87, we call against the downgrade and expect a sharp technical mean-reversion move higher. Completed 5D OHLCV History: 2026-10-19: Open 30.20, High 30.80, Low 30.00, Close 30.50, Vol 6100000 2026-10-20: Open 30.50, High 31.00, Low 30.20, Close 30.70, Vol 6200000 2026-10-21: Open 30.60, High 31.10, Low 30.30, Close 30.80, Vol 5900000 2026-10-22: Open 30.75, High 31.00, Low 30.10, Close 30.41, Vol 6300000 2026-10-23: Open 30.40, High 30.90, Low 30.10, Close 30.41, Vol 6400000 return_5d_pct = -0.30% high_20d = 32.73, low_20d = 14.59 avg_volume_20d = 10505680 Data source: NASDAQ / MarketChameleon regular session splits-adjusted. Price Action & Thesis Check: - Catalyst: Citigroup downgrade to Neutral with a $15.00 price target on 2026-10-27. - Counter-evidence: Further institutional dumping following director insider sales. - Invalidation level: Breach below $14.50 52-week low. Intraday Evidence at Answering Time: - latest_price: 15.71 USD - quote_time: 2026-10-26T16:00:00-04:00 - source: https://marketchameleon.com/Overview/XP/Summary/ - Status: Prior close quote. - PARTIAL SESSION: Not available at publication time. - Observed event reaction: -48.37% move on 2026-10-26. We expect a recovery bounce over the 1-day forecast window.
   Citigroup downgraded to Neutral, target $15 on 2026-10-27 — source
   Return: -1.95%; alpha: -2.28%.
4. DY — confidence 70%. Dycom Industries was initiated with a Market Perform rating by Oppenheimer on 2026-10-27. The stock has suffered a heavy decline from its 52-week highs near $566 down to ~$224. Consensus among other Street analysts remains Moderate Buy with average targets over $500. With strong fundamentals (Q2 EPS beat of $5.29 vs $4.72) and an active $150M buyback program, the initiation provides a catalyst for price stabilization and continuation higher. Completed 5D OHLCV History: 2026-10-19: Open 230.00, High 235.00, Low 226.00, Close 228.50, Vol 620000 2026-10-20: Open 229.00, High 232.00, Low 225.00, Close 227.10, Vol 610000 2026-10-21: Open 227.00, High 230.00, Low 223.00, Close 225.80, Vol 640000 2026-10-22: Open 226.00, High 228.00, Low 222.00, Close 225.16, Vol 630000 2026-10-23: Open 224.00, High 225.00, Low 220.18, Close 224.56, Vol 657300 return_5d_pct = -1.72% high_20d = 294.45, low_20d = 215.28 avg_volume_20d = 645245 Data source: Barchart / NYSE regular session splits-adjusted. Price Action & Thesis Check: - Catalyst: Coverage initiated by Oppenheimer with Market Perform rating on 2026-10-27. - Counter-evidence: Broader industrial sector weakness and high technical beta volatility. - Invalidation level: A fall below $215.00 level. Intraday Evidence at Answering Time: - latest_price: 228.68 USD - quote_time: 2026-10-27T09:30:00-04:00 - source: https://www.marketbeat.com/instant-alerts/analyst-dycom-industries-nyse-dy-coverage-initiated-by-analysts-at-oppenheimer-2026-10-27/ - Status: PARTIAL SESSION open quote. - PARTIAL SESSION: Open 228.68. - Observed event reaction: +1.83% move from $224.56 close to $228.68 open. Expect continued upside over the forecast horizon.
   Oppenheimer initiated coverage to Market Perform on 2026-10-27 — source
   Return: -0.27%; alpha: -0.60%.
5. AAOI — confidence 68%. Applied Optoelectronics saw a price target cut from Needham & Company LLC from $190 to $170 on 2026-10-27 while keeping a Buy rating. The new target of $170 still implies an upside of over 130% from the current price level around $71.94. Given the strong momentum in optical networking and AI datacenter demand, we expect the stock to resume its upward trajectory following this minor target recalibration. Completed 5D OHLCV History: 2026-10-19: Open 68.00, High 70.50, Low 67.00, Close 69.20, Vol 9800000 2026-10-20: Open 69.50, High 71.00, Low 68.20, Close 70.10, Vol 10100000 2026-10-21: Open 70.00, High 72.00, Low 69.10, Close 70.80, Vol 10400000 2026-10-22: Open 70.50, High 71.80, Low 68.50, Close 69.50, Vol 9900000 2026-10-23: Open 69.00, High 71.50, Low 67.80, Close 67.51, Vol 10270000 return_5d_pct = -2.44% high_20d = 73.27, low_20d = 62.10 avg_volume_20d = 10270000 Data source: NASDAQ / MarketChameleon regular session splits-adjusted. Price Action & Thesis Check: - Catalyst: Price target cut to $170 from $190 by Needham & Company LLC while maintaining Buy rating on 2026-10-27. - Counter-evidence: High implied volatility (110% IV30) causing swings. - Invalidation level: A breakdown below $65.00 support. Intraday Evidence at Answering Time: - latest_price: 71.94 USD - quote_time: 2026-10-26T16:00:00-04:00 - source: https://marketchameleon.com/Overview/AAOI/IV/ - Status: Prior close quote. - PARTIAL SESSION: Not available at publication time. - Observed event reaction: +6.56% move on 2026-10-26. We project continued upward momentum over the 1-day forecast window.
   Needham & Company LLC cut its target to Buy, target $170 (from $190) on 2026-10-27 — source
   Return: 3.93%; alpha: 3.60%.

Full prediction and audit record

Grok 4.7

Scoring window: Oct 27, 10:50 AM EDT → Oct 28, 10:50 AM EDT.

View full picks and reasoning

Selective short-term reactions to fresh analyst actions persist into the next session. Upgrades tied to AI infrastructure visibility and oversold pullbacks should see modest follow-through, while valuation-driven downgrades after large runs face continued pressure. Broader tape remains choppy ahead of macro events.

1. AVGO — confidence 72%. DA Davidson upgraded Broadcom to Buy from Neutral and raised the price target to 400 from 350 on 2026-10-27, citing Anthropic's S-1 filing as evidence the AI cycle is not over and that AVGO's ~16x 2027 EPS multiple embeds near-zero probability of the deals materializing (Gil Luria). The stock has already reacted positively, rising ~3% into the session after a prior close of 329.17. Path into the action showed consolidation after a multi-week pullback from the mid-370s, with the Oct 26 session closing near the high of its range on solid volume. Five completed sessions (oldest to newest): 2026-10-20 O334.00 H341.10 L330.80 C334.37 V15.95M; 2026-10-21 O338.03 H339.24 L332.29 C337.80 V17.12M; 2026-10-22 O326.53 H330.82 L321.02 C323.24 V28.14M; 2026-10-23 O321.50 H327.70 L320.23 C321.68 V15.92M; 2026-10-26 O324.53 H332.12 L323.25 C329.17 V18.65M. return_5d_pct approximately -1.6 (vs prior close near 334.6). high_20d near 380.8, low_20d near 320.2, avg_volume_20d ~21M shares. Volume on the bounce day was in line with average; no clear exhaustion. Catalyst is a fundamental re-rating of AI custom silicon visibility rather than pure sentiment. Strongest counter-evidence is that single-analyst upgrades on mega-caps often fade quickly without peer corroboration or estimate revisions. Price/volume supports short-term continuation of the relief bounce. Invalidation would be a close back below 330 on rising volume or a broader semiconductor risk-off. Latest quote ~340 USD at ~10:40 EDT 2026-10-27 (live/regular session, source https://finance.yahoo.com/quote/AVGO); partial session open ~339.4, high so far ~345.7, low ~337. Much of the initial reaction is reflected, but residual upside remains if AI sentiment holds. Source history: Yahoo Finance regular sessions.
   DA Davidson (Gil Luria) upgraded to Buy, target $400 (from $350) on 2026-10-27 — source
   Return: 1.95%; alpha: 1.63%.
2. MELI — confidence 68%. Citigroup upgraded MercadoLibre to Buy from Neutral and set a 2050 target (trimmed from 2100) on 2026-10-27, viewing the recent sharp pullback as an attractive entry as the company is expected to grow materially faster than local markets even with higher Brazilian rates (Joao Pedro Soares). Stock gapped down hard on Oct 26 amid Brazil election results and closed at 1668.72 after trading as low as ~1571; it has bounced ~2% so far today. Five completed sessions: 2026-10-20 O1838.85 H1880.18 L1826.16 C1879.50 V0.50M; 2026-10-21 O1865.86 H1892.10 L1840.93 C1854.88 V0.35M; 2026-10-22 O1842.55 H1856.74 L1803.10 C1824.96 V0.42M; 2026-10-23 O1801.01 H1824.64 L1792.21 C1810.15 V0.38M; 2026-10-26 O1578.25 H1671.48 L1570.76 C1668.72 V2.41M. return_5d_pct approximately -11.2. high_20d near 1892, low_20d near 1571, avg_volume_20d ~0.55M. The Oct 26 volume spike and long lower wick suggest selling climax; subsequent bounce on lighter volume is constructive for a short-term relief. Catalyst is a fundamental valuation reset after oversold political reaction rather than new growth news. Strongest counter-evidence is ongoing Brazil macro risk and margin concerns that could reassert. Price/volume favors short-term continuation of the bounce. Invalidation would be a retest and close below 1650 or renewed heavy selling. Latest quote ~1705-1707 USD at ~10:30 EDT 2026-10-27 (live/regular, source https://stockanalysis.com/stocks/meli/); partial open ~1706, high so far ~1728, low ~1672. Observed reaction from prior close is positive; further upside expected if the oversold bounce holds. Source history: Yahoo Finance.
   Citigroup (Joao Pedro Soares) upgraded to Buy, target $2050 (from $2100) on 2026-10-27 — source
   Return: -2.79%; alpha: -3.11%.
3. MTSI — confidence 65%. Raymond James upgraded MACOM Technology Solutions to Outperform from Market Perform with a 300 target on 2026-10-27 ahead of September-quarter results, citing multiple growth opportunities after a prior pullback (Melissa Fairbanks). Stock closed Oct 26 at 243.58 after a recovery day and is up ~3% so far today. Five completed sessions: 2026-10-21 O269.84 H274.33 L265.00 C273.05 V1.11M; 2026-10-22 O260.89 H260.89 L227.27 C229.73 V2.67M; 2026-10-23 O228.57 H241.26 L223.63 C236.24 V1.13M; 2026-10-26 O236.61 H246.87 L233.90 C243.58 V1.28M (plus prior session context). return_5d_pct approximately -10.8 from the Oct 21 area. high_20d near 303-306 range, low_20d near 224, avg_volume_20d ~1.5M. Recent sessions show a sharp selloff then bounce; volume elevated on the down day but not extreme on the recovery. Catalyst is a rating upgrade into earnings rather than a fundamental revision already known. Strongest counter-evidence is the still-elevated valuation and prior downgrades/target cuts in the name. Price/volume supports modest continuation of the bounce into the window. Invalidation would be a failed hold of 240 or a sharp reversal on rising volume. Latest quote ~251-252 USD at ~10:30 EDT 2026-10-27 (live/regular, source https://www.gurufocus.com/stock/MTSI); partial open ~251, high so far ~255. Reaction is positive; further modest upside expected. Source history: Yahoo Finance.
   Raymond James (Melissa Fairbanks) upgraded to Outperform, target $300 on 2026-10-27 — source
   Return: 1.19%; alpha: 0.87%.
4. HUBS — confidence 70%. UBS downgraded HubSpot to Neutral from Buy and raised the target to 310 from 290 on 2026-10-27, citing uneven SMB/new-logo demand, nascent AI monetization, intensifying competition, and pricing transition friction after a >30% rally over the past month (Taylor McGinnis). Stock is down ~4% so far today from the prior close of 263.99. Five completed sessions: 2026-10-20 O240.01 H252.32 L239.57 C250.76 V1.15M; 2026-10-21 O250.41 H254.90 L247.00 C249.90 V0.64M; 2026-10-22 O253.80 H268.60 L253.42 C267.19 V1.36M; 2026-10-23 O267.52 H271.54 L262.27 C270.88 V0.87M; 2026-10-26 O270.88 H271.60 L257.89 C263.99 V0.82M. return_5d_pct approximately +5.3. high_20d near 271.6, low_20d near 227, avg_volume_20d ~1.4M. Recent path shows a sharp recovery rally with the latest session failing near highs and closing lower. Catalyst is a fundamental caution on near-term demand rather than pure sentiment. Strongest counter-evidence is that the target was actually raised and some peers remain constructive. Price/volume shows early selling pressure consistent with the downgrade; further downside is favored short-term. Invalidation would be a quick reclaim of 260 on strong volume or positive channel checks. Latest quote ~252-253 USD at ~10:30 EDT 2026-10-27 (live/regular, source https://stockanalysis.com/stocks/hubs/); partial open ~256.8, high so far ~262, low ~252. Observed reaction is negative; residual downside expected. Source history: Yahoo Finance.
   UBS (Taylor McGinnis) downgraded to Neutral, target $310 (from $290) on 2026-10-27 — source
   Return: -0.51%; alpha: 0.19%.
5. MRNA — confidence 67%. William Blair downgraded Moderna to Market Perform from Outperform on 2026-10-27 (Myles Minter), citing valuation after a 545% YTD rally and ~250% surge since August trial news; the firm views the current price as already embedding high probability of success across oncology indications. Stock is down ~4-5% so far today from the prior close of 198.85. Five completed sessions: 2026-10-20 O226.03 H243.98 L216.65 C242.08 V16.86M; 2026-10-21 O242.20 H254.48 L239.55 C245.81 V16.01M; 2026-10-22 O240.13 H241.26 L180.80 C202.63 V49.95M; 2026-10-23 O196.69 H206.97 L183.00 C200.10 V21.52M; 2026-10-26 O186.90 H203.81 L181.65 C198.85 V17.05M. return_5d_pct approximately -17.9. high_20d near 254.5, low_20d near 180.8, avg_volume_20d ~20M+. The path shows a sharp multi-day selloff after the trial data with elevated volume on the big down day, consistent with profit-taking. Catalyst is a valuation caution rather than new negative science. Strongest counter-evidence is that the melanoma data were viewed as supportive by the firm and some other analysts remain more constructive. Price/volume favors continued pressure in the near term. Invalidation would be a strong reclaim of 195-200 on rising volume or fresh positive pipeline commentary. Latest quote ~189-190 USD at ~10:30 EDT 2026-10-27 (live/regular, source https://finance.yahoo.com/quote/MRNA/); partial open ~193, high so far ~194, low ~180. Observed reaction is negative; further downside expected. Source history: Yahoo Finance.
   William Blair (Myles Minter) downgraded to Market Perform on 2026-10-27 — source
   Return: 11.10%; alpha: -11.42%.

Full prediction and audit record

Claude Sonnet 5.5

Scoring window: Oct 27, 10:51 AM EDT → Oct 28, 10:51 AM EDT.

View full picks and reasoning

Tape is risk-on in AI and semiconductors on Oct 27 (SOXX up about 2% early) after Anthropic's IPO filing, while software and fintech names with downgrades are drifting lower. Analyst actions are mostly valuation or near-term-demand calls on stocks that already moved, so I keep expected moves small and confidence moderate. Daily OHLCV history could not be verified from accessible sources, so those fields are null throughout.

1. AVGO — confidence 45%. Catalyst (fact): D.A. Davidson (Gil Luria) upgraded Broadcom to Buy from Neutral and raised its target to $400 from $350 on Oct 27, citing Anthropic's IPO filing and the AI capex cycle. Anthropic's filing describes Broadcom as a supplier and lessor of compute under non-cancelable leases and shows a $63B financing vehicle. Published_at is the date at 00:00 US Eastern; the exact note time was not found. Inference: this is a change in the demand-visibility narrative, not just sentiment, but Davidson's thesis depends on Anthropic completing its IPO and OpenAI raising capital, which is not assured. Price path before action: prior close about 329.17 (derived from the $400 target implying 21.52% upside per MarketBeat; source https://www.marketbeat.com/instant-alerts/analyst-broadcom-nasdaq-avgo-stock-bumped-up-to-buy-by-da-davidson-2026-10-27/). Observed reaction: latest_price 339.90, quote_time 2026-10-27T09:23:00-04:00 (article timestamp, early regular-session trade, freshness approximate), source https://247wallst.com/investing/2026/10/27/broadcom-rises-3-on-da-davidson-upgrade-and-400-target-tied-to-anthropic-ipo-nvidia-and-amd-edge-higher/. Event-to-quote move is about +3.3% (339.90 vs 329.17). Other outlets reported +4% or more at the open, so the quote is already stale. Expected after the quote: modest continuation of about 1.5% as chips stay bid; a lot of the upgrade appears already priced into the gap. Strongest counter-evidence: Broadcom backs part of the financing (customer-concentration and credit exposure), and gap-ups on upgrades often fade intraday. Invalidation: a close back below the prior close of about 329.17, or news that Anthropic delays or cancels the IPO. Daily OHLCV: daily_5d null; return_5d_pct null; high_20d null; low_20d null; avg_volume_20d null (could not verify the 20-session mean; a Sep 30 article cited an average session volume of 25,143,646, which is not the required measure). Partial-session open, high, low and cumulative volume: null (not verified). Relative intraday volume cannot be established. Liquidity: market cap about 1.61T (4.73B shares x 339.90); avg_dollar_volume_20d_usd is a rough estimate (25.14M shares x 339.90), not the required 20-session mean.
   D.A. Davidson (Gil Luria) upgraded to Buy, target $400 (from $350) on 2026-10-27 — source
   Return: 1.83%; alpha: 1.52%.
2. HUBS — confidence 40%. Catalyst (fact): UBS (Taylor McGinnis) downgraded HubSpot to Neutral from Buy on Oct 27 and raised its target to $310 from $290. The analyst cited checks pointing to uneven small-business and new-customer demand, after a gain of more than 30% over the past month. Published_at is the date at 00:00 US Eastern; the exact time was not verified. Inference: the demand commentary is a fundamentals concern, but the higher target and the peer re-rating argument are valuation-based. Price path before action: stock up more than 30% in the prior month; a verified pre-event price with timestamp was not found, so it is null. Observed reaction: latest_price 264, source https://www.investing.com/news/analyst-ratings/ubs-downgrades-hubspot-stock-rating-on-demand-concerns-93CH-4974344, quote_time null (the page time zone was not stated, so freshness cannot be verified), marked as a delayed or unspecified regular-session quote. The page showed a -2.54% marker, which I cannot confirm as the event-to-quote move. Expected after the quote: a further drift of about 2% lower as the post-rally unwind continues. Strongest counter-evidence: the new $310 target sits above the price, several brokers kept Buy ratings (Canaccord $300, Needham $300), and a 7% layoff and cost reset is a supportive fundamental. Price and volume evidence is limited, so I treat continuation versus reversal as unsettled. Invalidation: a sustained move above the roughly 270.9 level implied by the -2.54% marker (unverified), or a peer software rally. Daily OHLCV: daily_5d null; return_5d_pct null; high_20d null; low_20d null; avg_volume_20d null (not verifiable). Partial-session figures: null. Relative intraday volume cannot be established. Liquidity: market cap 13.2B per Investing.com; avg_dollar_volume_20d_usd is a rough estimate from a 90-day average volume of about 1.73M shares (a Weiss Ratings article, date unclear) x 264.
   UBS (Taylor McGinnis) downgraded to Neutral, target $310 (from $290) on 2026-10-27 — source
   Return: -0.38%; alpha: 0.07%.
3. MRNA — confidence 40%. Catalyst (fact): William Blair (Myles Minter) cut Moderna to Market Perform from Outperform with no price target, citing valuation after a 545% year-to-date rise and a gain of nearly 250% since the August Phase 3 INTerpath-001 melanoma data. It says the price already implies a 70-75% probability of success in other tumor types. Sources disagree on the date: Benzinga and Investing.com say Monday Oct 26, MarketBeat and GuruFocus say Oct 27. Published_at is therefore Oct 26 at 00:00 US Eastern, date only, and both dates fall inside the window. Inference: this is a valuation call with no change to the pipeline facts. Price path before action: about 198.85 prior close (MarketBeat; the stock had already fallen 17.9% over the prior week). Observed reaction: latest_price 192.79, quote_time 2026-10-27T09:11:13-04:00, pre-market, source https://www.benzinga.com/trading-ideas/movers/26/10/62618658/william-blair-takes-a-shot-at-moderna-stock-downgrade-to-market-perform-after-a-545-run. The observed move from prior close to that quote is -3.05%. Expected after the quote: about 3% further downside as momentum unwinds. This is a highly volatile name, and part of the move is already in the premarket price. Strongest counter-evidence: a mean analyst target near 107 sits far below the price, yet the stock keeps trading on cancer-vaccine optimism. Next earnings are Nov 5 (TrendSpider), outside the window. Invalidation: a reclaim of roughly 198.85 on higher volume, or positive oncology data flow. Daily OHLCV: daily_5d null; return_5d_pct null; high_20d null; low_20d null; avg_volume_20d null (not verifiable). Partial-session figures: null. Relative intraday volume cannot be established. Liquidity: market cap 79.4B; avg_dollar_volume_20d_usd null because no verified 20-session volume figure was found, though the 79.4B market cap indicates ample liquidity.
   William Blair (Myles Minter) downgraded to Market Perform on 2026-10-26 — source
   Return: 11.68%; alpha: -11.99%.
4. XYZ — confidence 30%. Catalyst (fact): Morgan Stanley (James Faucette) downgraded Block to Equal-weight from Overweight and cut its target to $80 from $90 on Monday Oct 26. It cited bullish sentiment, a near-term slowdown in Cash App Borrow originations as loans move from four to six weeks, higher credit losses (loss rate 3.3% rising to a peak of 4.5% in Q4 2027) and competition. Published_at is the date at 00:00 US Eastern. Block reports Q3 on Nov 3 per TradingView (other pages say Nov 4-5), after the window. Price path before action: Friday close 76.46 (Benzinga). Observed reaction: Monday close 74.55 (-2.50%), after-hours 72.81, source https://www.marketscreener.com/news/block-shares-fall-after-morgan-stanley-downgrade-ce785cdcdf8ff226. Latest_price 72.81, quote_time 2026-10-26T19:59:59-04:00, extended-hours, prior to the Oct 27 session, so it is not a live quote. Event-to-quote move is about -4.8% (72.81 vs 76.46). Expected after the quote: another 1.5% lower, as the credit-loss narrative gets repriced into earnings. Strongest counter-evidence: about 4.8% of the downside is already in the after-hours price, the consensus target of about 98 is far above the price, and analysts broadly stay at Buy. Invalidation: a reclaim of the 76.46 pre-downgrade close, or strong credit-quality commentary from the company ahead of earnings. Daily OHLCV: daily_5d null; return_5d_pct null; high_20d null; low_20d null; avg_volume_20d null (not verifiable). Partial-session figures: null. Relative intraday volume cannot be established. Liquidity: market cap about 44.4B (595.18M shares x 74.55); avg_dollar_volume_20d_usd is a rough estimate (about 4.55M average shares per CapEdge x 74.55).
   Morgan Stanley (James Faucette) downgraded to Equal-weight, target $80 (from $90) on 2026-10-26 — source
   Return: -0.13%; alpha: -0.17%.
5. TSLA — confidence 30%. Catalyst (fact): Barclays (Dan Levy) upgraded Tesla to Overweight from Equal-Weight and raised its target to $450 from $370 on Monday Oct 26. Other firms raised targets around the same time: Morgan Stanley to $410 (Equal Weight, Andrew Percoco) and Piper Sandler to $475 (Overweight, Alexander Potter). Published_at is the date at 00:00 US Eastern. Inference: a cluster of post-earnings target raises supports momentum, but I have not verified the earnings details behind it. Price path before action: Friday close 372.22 (Benzinga), which is also my latest verified stock price; reference_price is that Oct 23 close, not an Oct 27 quote, and the intraday quote for the stock was not verified (latest_price null; quote_time null). A Binance Futures tokenized contract showed about 395.96 (+4.03%) on Oct 27, but that is not the equity quote and is not used as one. Event-to-quote move: null because there is no verified equity quote. Expected after the current price: about 1.5% further upside on analyst momentum. Strongest counter-evidence: per one report the contract was pressing the upper Bollinger Band with an overbought stochastic reading, so a pullback after a 4% pop is plausible, and the stock may already have priced in most of the upgrade. Invalidation: a break below about 372.34 support on the contract (unverified for the equity), or a failure to hold the post-upgrade gap. Daily OHLCV: daily_5d null; return_5d_pct null; high_20d null; low_20d null; avg_volume_20d null (not verifiable). Partial-session figures: null. Relative intraday volume cannot be established. Liquidity: market_cap_usd and avg_dollar_volume_20d_usd are null because not verified; Tesla is far above the $1B and $20M thresholds by any reasonable reading, but I could not verify the exact figures.
   Barclays (Dan Levy) upgraded to Overweight, target $450 (from $370) on 2026-10-26 — source
   Return: -0.48%; alpha: -0.78%.

Full prediction and audit record

Muse Spark 1.1

Scoring window: Oct 27, 10:55 AM EDT → Oct 28, 10:55 AM EDT.

View full picks and reasoning

Broad market near highs with AI infrastructure financing supporting semis, while selective downgrades in payments and SaaS create tactical mean-reversion setups. Analyst actions Oct 26-27 cluster around earnings beats (Ryder, Cadence) and AI capex visibility (Broadcom), suggesting continuation into next session, with HubSpot vulnerable after 30% run.

1. AVGO — confidence 78%. Thesis: DA Davidson upgraded AVGO from Neutral to Buy and raised target to $400 from $350 on Oct 27, citing Anthropic IPO filing disclosing $224.5B compute commitments and $63B bank+ Blackstone financing for Broadcom AI infrastructure. Stock closed Oct 26 at $329.17 up 2.33% after hitting 6-month low, premarket Oct 27 to $340.10. Expect continuation as upgrade validates AI cycle not over and financing de-risks revenue visibility, driving alpha vs SPY in next session. Risk: high valuation and Alphabet diversifying TPU suppliers to MediaTek. Historical 5-day bars (oldest to newest, source: https://stockanalysis.com/stocks/avgo/history/, US Eastern regular session, split-adjusted): - 2026-10-20: open 334.00 high 341.10 low 330.80 close 334.37 volume 15951817 - 2026-10-21: open 338.03 high 339.24 low 332.29 close 337.80 volume 17123631 - 2026-10-22: open 326.53 high 330.82 low 321.02 close 323.24 volume 28139147 - 2026-10-23: open 321.50 high 327.70 low 320.23 close 321.68 volume 15917005 - 2026-10-26: open 324.53 high 332.12 low 323.25 close 329.17 volume 18646725 return_5d_pct: -1.62% (329.17 / 334.59 close on 2026-10-19 -1) high_20d: 380.84 low_20d: 320.23 avg_volume_20d: 21538749 shares History source: https://stockanalysis.com/stocks/avgo/history/ Price Action & Thesis Check: Catalyst is fundamental/business expectation change (Anthropic financing) plus sentiment upgrade. Verified facts: $63B financing reported by WSJ Oct 26 after close, DA Davidson upgrade published 2026-10-27T11:06:45Z with target $400. Inference: IPO proceeds help Broadcom meet growth next 2 years. Price path before event: decline from $376 Oct 7 high to $321 Oct 23 low (-14%). Reaction so far: bounce +2.33% Oct 26, intraday Oct27 to $345.67 high. Counter-evidence: stock below 50-day MA $356.76 and 200-day $367.07, 14-day RSI 39.6 bearish, still far from $495 52-week high. Volume: Oct 26 18.6M vs avg 21.2M, Oct22 28M on down day indicating capitulation. Evidence supports continuation rather than exhaustion as upgrade fresh and financing new. Invalidation: close below Oct 23 low $320.23 or if $63B financing vehicle fails to materialize; observable future event: any disclosure that Anthropic reduces Broadcom purchases. Intraday Evidence: - latest_price: 339.00 USD at 2026-10-27T10:48:00-04:00 source https://stockanalysis.com/stocks/avgo/history/ (regular-session partial, live) - quote_time: 2026-10-27T10:48:00-04:00 - reference_price consistent at 339.00, data_date 2026-10-27, price_source https://stockanalysis.com/stocks/avgo/history/ - Today's partial session: open 339.87 high_so_far 345.67 low_so_far 336.87 cumulative_volume 7248611 as of 2026-10-27T10:48:00-04:00 source https://stockanalysis.com/stocks/avgo/history/ PARTIAL SESSION, relative intraday volume cannot be established vs full-day avg without same-time baseline - Pre-event price: 321.68 close on 2026-10-23 source https://stockanalysis.com/stocks/avgo/history/ observed event-to-quote move: +5.38% (339.00/321.68-1) - Catalyst reflection: financing after close Oct26 and upgrade pre-market Oct27 only partly reflected; ~5% move vs 21% upside to target suggests room - Remaining window expectation: further upside toward $345 resistance in window from 10:47 EDT Oct27 to 10:47 EDT Oct28; elapsed move minimal as window just started
   DA Davidson upgraded to Buy, target $400 (from $350) on 2026-10-27 — source
   Return: 1.64%; alpha: 1.40%.
2. CDNS — confidence 75%. Thesis: Robert W Baird raised CDNS target to $440 from $420 and kept Outperform on Oct 27 after Q3 beat Oct 26: EPS $2.11 vs $2.05 consensus, revenue $1.63B vs $1.61B, up 22% YoY, record backlog $8.2B, raised FY growth to ~21% and expanded buyback $2.5B. Stock closed Oct 26 at $322.17 up 1.79%, intraday Oct27 to $333.37 up 3.48%. Expect continuation as EDA demand for AI chip complexity remains firm and backlog improves visibility, driving outperformance vs SPY. Historical 5-day bars (oldest to newest, source: https://stockanalysis.com/stocks/cdns/history/, US Eastern regular session, split-adjusted): - 2026-10-20: open 323.18 high 325.64 low 316.72 close 319.87 volume 1741623 - 2026-10-21: open 324.50 high 331.50 low 322.84 close 326.07 volume 2172591 - 2026-10-22: open 318.42 high 319.47 low 306.39 close 309.65 volume 2893495 - 2026-10-23: open 307.57 high 318.15 low 305.19 close 316.49 volume 2320977 - 2026-10-26: open 316.98 high 331.65 low 315.35 close 322.17 volume 4500965 return_5d_pct: -1.13% (322.17 / 325.86 close on 2026-10-19 -1) high_20d: 361.91 low_20d: 305.19 avg_volume_20d: 2317009 shares History source: https://stockanalysis.com/stocks/cdns/history/ Price Action & Thesis Check: Catalyst is fundamental: earnings beat and raised outlook plus $8.1B backlog, target raise validates. Verified fact: Q3 results Oct26, backlog record, guidance increase. Inference: AI-driven chip design sustains EDA. Price path before: slide from Oct6 intraday high $361.91 to Oct23 low $305.19 (-15.7%), then recovery. Reaction: +2.21% Oct23, +1.79% Oct26, intraday Oct27 +3.48% to $333.48 high, closing near high of range. Counter-evidence: premium P/E 64x, margin pressure noted, stock still -22.7% below $416.69 June high. Volume: Oct26 4.5M vs avg 0.82M daily avg (from Intelligent Investor) indicating high interest, supports continuation. Not exhaustion as move from low still modest. Invalidation: close below Oct23 low $305.19 or if backlog growth reverses; observable event: Synopsys peer weakness or semi capex cut. Intraday Evidence: - latest_price: 333.37 USD at 2026-10-27T10:35:00-04:00 source https://stockanalysis.com/stocks/cdns/history/ (regular-session partial, live) - quote_time: 2026-10-27T10:35:00-04:00 - reference_price consistent at 333.37, data_date 2026-10-27, price_source https://stockanalysis.com/stocks/cdns/history/ - Today's partial session: open 325.96 high_so_far 333.48 low_so_far 323.68 cumulative_volume 722539 as of 2026-10-27T10:35:00-04:00 source https://stockanalysis.com/stocks/cdns/history/ PARTIAL SESSION - Pre-event price: 316.49 close on 2026-10-23 source https://stockanalysis.com/stocks/cdns/history/ observed event-to-quote move: +5.33% (333.37/316.49-1) reflecting earnings + target raise - Catalyst reflection: earnings after close Oct26 and target raise Oct27 morning ~5% reflected, but target $440 implies 36% upside, suggests further follow-through possible in next session - Remaining window expectation: continuation toward $340-350 if EDA momentum holds, alpha vs SPY
   Robert W. Baird raised its target to Outperform, target $440 (from $420) on 2026-10-27 — source
   Return: 3.07%; alpha: 2.82%.
3. R — confidence 68%. Thesis: Susquehanna raised Ryder System target to $318 from $280 and kept Positive on Oct 27 after Q3 beat Oct22: EPS $4.33 vs $4.15 consensus, revenue $2.76B, up 8.3% YoY, 201st consecutive dividend. Stock closed Oct 26 at $282.11 up 4.14% to new all-time high $285.57, after +10.49% Oct22. Target raise from $280 to $318 implies 13.9% upside from current. Expect further upside as fleet management demand and supply chain strength plus low float drives momentum vs SPY, though low volume Oct27 indicates pause. Historical 5-day bars (oldest to newest, source: https://stockanalysis.com/stocks/r/history/, US Eastern regular session, split-adjusted): - 2026-10-20: open 235.22 high 240.68 low 230.99 close 237.38 volume 358936 - 2026-10-21: open 238.60 high 241.25 low 237.15 close 240.31 volume 326774 - 2026-10-22: open 250.82 high 266.14 low 250.54 close 265.53 volume 620117 - 2026-10-23: open 270.00 high 271.12 low 258.08 close 270.90 volume 684642 - 2026-10-26: open 273.48 high 285.57 low 273.48 close 282.11 volume 523088 return_5d_pct: +19.52% (282.11 / 236.04 close on 2026-10-19 -1) high_20d: 285.57 low_20d: 223.30 avg_volume_20d: 346014 shares History source: https://stockanalysis.com/stocks/r/history/ Price Action & Thesis Check: Catalyst is fundamental: earnings beat and raised targets from multiple firms (Barclays $300->$315, JPMorgan $298->$315, Wells $300->$305, Citi $285->$302, Susquehanna $280->$318). Verified fact: Q3 EPS beat $0.18, target raise published 2026-10-27T14:24:41Z. Inference: transportation upcycle. Price path before: flat ~$238 early Oct, then gap up Oct22 +10.49% on earnings. Reaction: continued +2.02% Oct23, +4.14% Oct26 to ATH. Counter-evidence: overvalued per GuruFocus 41.9% above GF Value $190.97, volume Oct26 523k vs 30-day avg 298k but Oct27 mid-day only 17k vs avg 361k per MarketBeat indicating exhaustion and lack of follow-through. Upper wick Oct26 (high $285.57 close $282.11) shows selling into strength. Still, breakout above $284 high could continue. Invalidation: close below Oct23 low $258.08 or breakdown below 50-day MA $243.11; observable event: freight demand drop or dividend cut. Intraday Evidence: - latest_price: 280.145 USD at 2026-10-27T10:47:00-04:00 source https://finnhub.io (regular-session, live) - quote_time: 2026-10-27T10:47:00-04:00 - reference_price consistent at 280.145, data_date 2026-10-27, price_source https://finnhub.io - Today's partial session: open 283.62 high_so_far 287.00 low_so_far 277.90 cumulative_volume 17144 as of mid-day Oct27 source https://www.marketbeat.com/instant-alerts/analyst-ryder-system-nyse-r-price-target-raised-to-31800-2026-10-27/ PARTIAL SESSION, low volume suggests pause not distribution yet, cannot compare directly to full-day avg - Pre-event price: 240.31 close on 2026-10-21 before earnings source https://stockanalysis.com/stocks/r/history/ observed event-to-quote move: +16.58% (280.145/240.31-1) - Catalyst reflection: earnings largely reflected (+17% in week), target raise today adds incremental 13.9% upside thesis, partly reflected in ATH but low volume pullback suggests not fully - Remaining window expectation: modest upside toward $285-288 if volume returns, alpha vs SPY if transportation momentum persists
   Susquehanna raised its target to Positive, target $318 (from $280) on 2026-10-27 — source
   Return: -1.59%; alpha: -1.84%.
4. XYZ — confidence 55%. Thesis: Morgan Stanley downgraded Block XYZ from Overweight to Equal Weight and cut target to $80 from $90 on Oct 26, citing valuation after run from $48 low. Stock closed Oct 26 at $74.55 down 2.50% on downgrade, after falling 3.24% Oct23. Downgrade appears fully priced: consensus Moderate Buy $95.61, 52-week high $86.92, stock now at $74.40 with P/E 26 and upcoming earnings Nov3. Expect oversold bounce vs SPY in next session as downgrade removes overhang and payments sentiment troughs. Historical 5-day bars (oldest to newest, source: https://stockanalysis.com/stocks/xyz/history/, US Eastern regular session, split-adjusted): - 2026-10-20: open 77.25 high 79.31 low 77.05 close 78.10 volume 3961912 - 2026-10-21: open 79.05 high 79.62 low 77.89 close 78.21 volume 2822066 - 2026-10-22: open 78.38 high 79.87 low 77.81 close 79.02 volume 3840263 - 2026-10-23: open 77.67 high 78.09 low 75.91 close 76.46 volume 5159410 - 2026-10-26: open 76.13 high 76.22 low 74.01 close 74.55 volume 5207177 return_5d_pct: -3.81% (74.55 / 77.50 close on 2026-10-19 -1) high_20d: 81.17 low_20d: 72.28 avg_volume_20d: 4474798 shares History source: https://stockanalysis.com/stocks/xyz/history/ Price Action & Thesis Check: Catalyst is sentiment (downgrade) not fundamental change; earnings beat Aug 5 $1.02 vs $0.48, revenue +9.3% YoY. Verified fact: downgrade published 2026-10-26T12:06:36Z, target $80 implies 7.34% upside from current. Inference: Morgan Stanley de-risking after strong YTD +14.3%. Price path before: downtrend from $82 Sep2 high, gap down. Reaction: -2.50% Oct26 on heavy volume 5.2M vs avg 4.55M, indicating capitulation. Counter-evidence: downgrade could lead to further cuts, Cash App bitcoin exposure risk, beta 2.55 high volatility. Volume: Oct26 volume above avg supports exhaustion not continuation of down move. Oversold bounce thesis not guaranteed. Invalidation: close below Sep30 low $73.19 or break of $70 psychological; observable event: another downgrade or pre-announcement before Nov3 earnings. Intraday Evidence: - latest_price: 74.40 USD at 2026-10-27T10:44:00-04:00 source https://stockanalysis.com/stocks/xyz/history/ (regular-session partial, live) - quote_time: 2026-10-27T10:44:00-04:00 - reference_price consistent at 74.40, data_date 2026-10-27, price_source https://stockanalysis.com/stocks/xyz/history/ - Today's partial session: open 74.82 high_so_far 75.46 low_so_far 73.79 cumulative_volume 649482 as of 2026-10-27T10:44:00-04:00 source https://stockanalysis.com/stocks/xyz/history/ PARTIAL SESSION, volume light vs full-day avg 4.47M, cannot assess unusual volume without same-time baseline - Pre-event price: 76.46 close on 2026-10-23 source https://stockanalysis.com/stocks/xyz/history/ observed event-to-quote move: -2.69% (74.40/76.46-1) reflecting downgrade - Catalyst reflection: downgrade largely reflected in -2.5% drop Oct26 plus intraday flat; further downside limited as target $80 above market - Remaining window expectation: bounce toward $76-77 (50-day MA $78.51) in window Oct27 10:47 EDT to Oct28 10:47 EDT, generating positive alpha if market stabilizes
   Morgan Stanley downgraded to Equal Weight, target $80 (from $90) on 2026-10-26 — source
   Return: -0.18%; alpha: -0.43%.
5. HUBS — confidence 60%. Thesis: UBS downgraded HUBS from Buy to Neutral and raised target to $310 from $290 on Oct27, citing uneven SMB and new logo demand, nascent AI monetization, intensifying down-market competition, go-to-market friction from pricing transition, and +30% run over past month making risk/reward balanced. Stock closed Oct26 at $263.99 down 2.54% after hitting $271.60 high, volume 822k. Expect further downside vs SPY as downgrade after parabolic rise triggers profit taking and valuation concerns (fair value $227, consensus Hold). Historical 5-day bars (oldest to newest, source: https://stockanalysis.com/stocks/hubs/history/, US Eastern regular session, split-adjusted): - 2026-10-20: open 240.01 high 252.32 low 239.57 close 250.76 volume 1147145 - 2026-10-21: open 250.41 high 254.90 low 247.00 close 249.90 volume 639194 - 2026-10-22: open 253.80 high 268.60 low 253.42 close 267.19 volume 1364456 - 2026-10-23: open 267.52 high 271.54 low 262.27 close 270.88 volume 874176 - 2026-10-26: open 270.88 high 271.60 low 257.89 close 263.99 volume 822967 return_5d_pct: +12.51% (263.99 / 234.63 close on 2026-10-19 -1) high_20d: 271.60 low_20d: 194.27 avg_volume_20d: 1141547 shares History source: https://stockanalysis.com/stocks/hubs/history/ Price Action & Thesis Check: Catalyst is sentiment/fundamental mix: demand concerns outweigh price target raise. Verified fact: downgrade published 2026-10-27T09:02:06Z, target up to $310. Inference: UBS sees balanced risk/reward after 30% surge. Price path before: strong uptrend from $197 Sep29 low to $271 Oct26 high (+37%), with gaps up Oct20 +6.87%, Oct22 +6.92%. Reaction: -2.54% Oct26 on high wick (high $271.60 close $263.99) indicating exhaustion. Counter-evidence: BTIG raised target $250->$300 Oct23, CRM sector strength could support. Volume: Oct22 1.36M above avg 1.14M, Oct26 822k below avg, suggests buying climax passed. Evidence supports reversal rather than continuation. Invalidation: close above Oct26 high $271.60 or new AI monetization proof; observable event: Q4 earnings Nov4 beat with seat growth re-acceleration. Intraday Evidence: - latest_price: 253.45472 USD at 2026-10-27T10:01:00-04:00 source https://finnhub.io (regular-session, delayed, official price 253.83 -10.16 -3.85% as of 10:01 AM EDT Oct27) - quote_time: 2026-10-27T10:01:00-04:00 - reference_price consistent at 253.45472, data_date 2026-10-27, price_source https://finnhub.io - Today's partial session: open 256.80 high_so_far 262.19 low_so_far 251.77 cumulative_volume not disclosed, but pre-market 259.25 down 1.80% at 05:29 EDT source https://stockanalysis.com/stocks/hubs/history/ PARTIAL SESSION - Pre-event price: 270.88 close on 2026-10-23 source https://stockanalysis.com/stocks/hubs/history/ observed event-to-quote move: -6.43% (253.45/270.88-1) reflecting downgrade after peak - Catalyst reflection: downgrade just published, down move ~6% from recent high suggests partially reflected but further downside likely as valuation extended and SMB demand concerns linger - Remaining window expectation: further decline toward $250-255 support in window Oct27 10:47 EDT to Oct28 10:47 EDT, negative alpha vs SPY if profit taking continues
   UBS Group downgraded to Neutral, target $310 (from $290) on 2026-10-27 — source
   Return: -0.48%; alpha: 0.23%.

Full prediction and audit record

GPT-6

Scoring window: Oct 27, 10:56 AM EDT → Oct 28, 10:56 AM EDT.

View full picks and reasoning

US equities are mixed to modestly positive on October 27, 2026, with SPY quoted at $765.89 at 10:24 EDT, up approximately 0.07%. Stock-specific analyst revisions and fundamental catalysts are generating considerably larger moves. Broadcom benefits from renewed AI infrastructure optimism following Anthropic's IPO filing, while Tesla is extending a Barclays-driven rally. HubSpot and Abbott face pressure from cautious analyst assessments, and Moderna remains volatile after positive melanoma vaccine trial results triggered a substantial sell-the-news decline. The Federal Reserve's October 27-28 meeting creates additional macro uncertainty. Its scheduled October 28 decision at 14:00 EDT is later than the expected end of this one-session forecast window, although anticipation could influence prices beforehand. The five directional forecasts favor selective positive momentum in AVGO and TSLA and continued weakness in HUBS, MRNA and ABT. These are prospective movements from each stock's actual ForecastNest submission price, not predictions of changes from the previous close. All five stocks meet the $5 minimum price, $1 billion market capitalization and $20 million average daily dollar-volume requirements. Historical calculations use the 20 completed regular sessions through October 26, excluding the unfinished October 27 session. Average dollar volume is calculated as the arithmetic mean of daily closing price multiplied by daily share volume. The reference quotes are timestamped observations and may precede the actual ForecastNest submission.

1. AVGO — confidence 69%. ANALYST ACTION: DA Davidson analyst Gil Luria upgraded Broadcom from Neutral to Buy and increased his target from $350 to $400. The action was reported October 27; its exact publication time was not independently established, so published_at uses midnight Eastern as a date-only placeholder. CATALYST: DA Davidson argues that Anthropic's IPO filing provides evidence that financing for large AI infrastructure commitments may remain available. Luria believes additional capital could support Broadcom's custom AI semiconductor revenue expectations. This is a verified change in the analyst's business outlook, not proof that projected customer spending will materialize. The underlying financing outlook is fundamentally relevant, while the immediate rating-driven move is partly sentiment. Catalyst source: https://www.investing.com/news/stock-market-news/broadcom-da-davidson-upgrades-avgo-says-anthropic-s1-shows-ai-cycle-isnt-over-4975085 PRE-EVENT PRICE PATH: AVGO declined from $334.37 on October 20 to $323.24 on October 22, with the October 22 session closing near its low on 28.14 million shares. It subsequently recovered to $329.17 on October 26, although that session's 18.65 million shares were below its 20-day average of 21.54 million. The recovery was encouraging but had not established a confirmed breakout from the 20-session range. OBSERVED REACTION: The verified pre-event reference is $329.17 at the October 26 regular-session close, 2026-10-26T16:00:00-04:00, from https://stockanalysis.com/stocks/avgo/history/. Latest_price=338.26 USD; quote_time=2026-10-27T10:39:00-04:00; quote_type=regular-session, provider-labelled real-time; source=https://stockanalysis.com/stocks/avgo/history/. The observed pre-event-close-to-quote change is +2.76%. October 27 PARTIAL SESSION, as of 10:39 EDT: open=339.87, high_so_far=345.67, low_so_far=336.87, cumulative_volume=6968479 shares. The price has moved above October 26's $332.12 high but retreated from its intraday peak and trades below its opening price. Much of the initial upgrade response is already reflected in the quote. No verified same-time-of-day volume baseline is available, so unusual relative intraday volume cannot be established. COMPLETED DAILY OHLCV: All dates are US Eastern regular trading sessions, 09:30-16:00 EDT. Fields are session_date, open, high, low, close, volume in shares. These are historical split-adjusted OHLC prices, not dividend-adjusted closes. The unfinished October 27 bar is excluded. 2026-10-20: 334.00, 341.10, 330.80, 334.37, 15951817 2026-10-21: 338.03, 339.24, 332.29, 337.80, 17123631 2026-10-22: 326.53, 330.82, 321.02, 323.24, 28139147 2026-10-23: 321.50, 327.70, 320.23, 321.68, 15917005 2026-10-26: 324.53, 332.12, 323.25, 329.17, 18646725 return_5d_pct=-1.62; calculation uses October 19 close=334.59 and October 26 close=329.17. high_20d=380.84; low_20d=320.23; avg_volume_20d=21538748.7 shares; avg_dollar_volume_20d_usd=7493872818. Historical source: https://stockanalysis.com/stocks/avgo/history/. THESIS: The analyst revision coincides with a credible reassessment of AI infrastructure financing. October 26's recovery and today's upside gap support a possible continuation over the remaining forecast window. Nevertheless, today's retreat from $345.67 shows that buyers are not controlling the entire session. The 20-day high remains substantially above the current price, so this is a recovery attempt rather than a 20-day breakout. The strongest counter-evidence is the high-volume October 22 decline, combined with today's upper wick and retreat below the opening price. A sustained return below $332.12, the previous completed-session high, would invalidate the immediate bullish gap-continuation thesis. A deterioration in expectations for AI customer financing is the principal fundamental risk. The expected +1.2% is incremental to the submission price, not the +2.76% already observed.
   DA Davidson (Gil Luria) upgraded to Buy, target $400 (from $350) on 2026-10-27 — source
   Return: 1.45%; alpha: 1.21%.
2. TSLA — confidence 64%. ANALYST ACTION: Barclays analyst Dan Levy upgraded Tesla from Equal-Weight to Overweight and increased his price target from $370 to $450. The upgrade was reported October 26; its exact publication time was not verified, so published_at uses midnight Eastern as a date-only placeholder. CATALYST: Barclays cited improving automotive growth expectations, strong energy storage demand, Robotaxi expansion and the possibility of a Tesla-SpaceX transaction. These are distinct components: operating growth and energy demand concern fundamental expectations, while the potential merger remains conditional and contributes a speculative valuation premium. The upgrade itself is verified, but a completed merger or agreed consideration is not established. Additional source: https://www.tipranks.com/news/tesla-stock-rises-in-premarket-as-barclays-upgrades-rating-and-lifts-price-target-by-20-oct-26. PRE-EVENT PRICE PATH: The previous five completed sessions were volatile rather than consistently bullish. Tesla closed at $386.47 on October 21, retreated to $374.58 on October 22, and ended October 23 at $372.22. This created scope for the October 26 upgrade to reverse a short-term decline. OBSERVED REACTION: The verified pre-event regular-session reference is October 23 close=$372.22 at 2026-10-23T16:00:00-04:00, source=https://stockanalysis.com/stocks/tsla/history/. October 26 then gained 5.21%, closing at $391.62 on 53.09 million shares. Latest_price=401.66 USD; quote_time=2026-10-27T10:40:00-04:00; quote_type=regular-session, provider-labelled real-time; source=https://stockanalysis.com/stocks/tsla/. The cumulative pre-event-close-to-quote change is +7.91%. October 27 PARTIAL SESSION, as of 10:40 EDT: open=397.76, high_so_far=404.00, low_so_far=395.25, cumulative_volume=16162958 shares. The current price exceeds the previous completed-session 20-day high of $397.27. Much of the immediate analyst catalyst has therefore already been capitalized into the price. No verified same-time-of-day volume baseline is available for the partial session. COMPLETED DAILY OHLCV: US Eastern regular sessions, 09:30-16:00 EDT. Fields are session_date, open, high, low, close, volume in shares. Split-adjusted OHLC, excluding today's unfinished bar and excluding dividend adjustment. 2026-10-20: 370.28, 377.59, 363.64, 373.71, 32123322 2026-10-21: 381.43, 388.84, 380.51, 386.47, 48875814 2026-10-22: 374.29, 388.86, 373.71, 374.58, 51610857 2026-10-23: 373.20, 377.32, 365.27, 372.22, 34762967 2026-10-26: 383.83, 397.27, 383.73, 391.62, 53090212 return_5d_pct=6.40; calculation uses October 19 close=368.06 and October 26 close=391.62. high_20d=397.27; low_20d=345.88; avg_volume_20d=36938234.4 shares; avg_dollar_volume_20d_usd=13728004449. Historical source: https://stockanalysis.com/stocks/tsla/history/. THESIS: October 26's advance was accompanied by volume approximately 43.7% above the completed-session 20-day average, strengthening the evidence that the upgrade attracted substantial participation. The October 26 upper wick shows some profit-taking, but the stock retained most of its session gain and has moved above the preceding 20-day high in today's partial session. This supports short-term momentum continuation. The strongest counter-evidence is the already realized 7.91% rise since the pre-event close, the elevated valuation, and the absence of agreed merger terms. A sustained decline below $391.62, the October 26 close, would undermine the breakout-continuation thesis. Disappointing merger developments or broader growth-stock weakness could also reverse the move. Expected additional appreciation is limited to +1.0%, recognizing that the initial repricing has already occurred.
   Barclays (Dan Levy) upgraded to Overweight, target $450 (from $370) on 2026-10-26 — source
   Return: -0.55%; alpha: -0.78%.
3. HUBS — confidence 72%. ANALYST ACTION: UBS analyst Taylor McGinnis downgraded HubSpot from Buy to Neutral while raising the price target from $290 to $310. This is a downgrade, not a target_raise action, because the rating changed. The action was reported October 27; the exact analyst publication time is unavailable, so published_at uses midnight Eastern as a date-only placeholder. CATALYST: UBS reported a more mixed near-term environment, including uneven small-business and new-customer demand, intensifying competition in the lower end of the market, early-stage AI monetization and possible sales friction from pricing changes. UBS also reduced its estimated fiscal 2027 constant-currency revenue growth from 14.5% to 13%. These analyst revisions affect expected business growth rather than merely sentiment. The higher $310 target reflects peer valuation re-rating and is important positive counter-evidence, not a contradiction in the recorded action. Source: https://www.investing.com/news/analyst-ratings/ubs-downgrades-hubspot-stock-rating-on-demand-concerns-93CH-4974344. PRE-EVENT PRICE PATH: HubSpot climbed sharply over the completed five-session window, from the October 19 close of $234.63 to October 26 close of $263.99. The 12.51% gain included strong October 20 and October 22 advances. However, October 26 reversed lower after opening at $270.88, reaching $271.60 and closing at $263.99. That session's 822967 shares were below the 20-day average of approximately 1.14 million, reducing conviction that the reversal was already decisive. OBSERVED REACTION: The verified pre-event quote is the October 26 close=$263.99 at 2026-10-26T16:00:00-04:00, source=https://stockanalysis.com/stocks/hubs/history/. Latest_price=253.33 USD; quote_time=2026-10-27T10:23:00-04:00; quote_type=regular-session, provider-labelled real-time; source=https://stockanalysis.com/stocks/hubs/. This quote was approximately 4.04% below the pre-event close. October 27 PARTIAL SESSION, as of 10:23 EDT: open=256.80, high_so_far=262.19, low_so_far=252.12, cumulative_volume=141869 shares. The price is below the session opening level and near the displayed low, indicating continued selling following the downgrade. Its initial negative reaction is already reflected in the quote, and the quote timestamp is older than those of several other selections. A same-time-of-day historical volume baseline was not verified. COMPLETED DAILY OHLCV: US Eastern regular sessions, 09:30-16:00 EDT. Fields are session_date, open, high, low, close, volume in shares. Split-adjusted OHLC, excluding dividend adjustment and the October 27 partial session. 2026-10-20: 240.01, 252.32, 239.57, 250.76, 1147145 2026-10-21: 250.41, 254.90, 247.00, 249.90, 639194 2026-10-22: 253.80, 268.60, 253.42, 267.19, 1364456 2026-10-23: 267.52, 271.54, 262.27, 270.88, 874176 2026-10-26: 270.88, 271.60, 257.89, 263.99, 822967 return_5d_pct=12.51; calculation uses October 19 close=234.63 and October 26 close=263.99. high_20d=271.60; low_20d=194.27; avg_volume_20d=1141547.3 shares; avg_dollar_volume_20d_usd=262201148. Historical source: https://stockanalysis.com/stocks/hubs/history/. THESIS: The downgrade creates a plausible catalyst for investors to reassess the sustainability of HubSpot's recent rebound. The combination of reduced growth estimates, Monday's reversal from the 20-day high and Tuesday's negative gap supports bearish continuation. The strongest counter-evidence is that UBS simultaneously increased its price target to $310 and the stock has recently demonstrated powerful upward momentum. Moreover, Monday's downside volume was not unusually high, and Tuesday's partial volume cannot establish institutional selling intensity without an intraday baseline. A sustained recovery above $262.19, the verified Tuesday partial-session high, would challenge immediate bearish continuation; a move back above $271.60 would invalidate the broader reversal thesis. Stronger customer-demand evidence or another positive analyst revision would also undermine the bearish case. The forecast concerns a further 1.5% decline after the current quote, not the 4.04% already observed.
   UBS (Taylor McGinnis) downgraded to Neutral, target $310 (from $290) on 2026-10-27 — source
   Return: -0.58%; alpha: 0.35%.
4. MRNA — confidence 59%. ANALYST ACTION: William Blair analyst Myles Minter downgraded Moderna from Outperform to Market Perform. The firm cited valuation concerns after an extraordinary year-to-date advance and the release of additional melanoma vaccine trial results. The action is reported in October 27 ratings coverage, although some news coverage describes the downgrade as occurring Monday. Therefore, its precise original issuance time is uncertain. The published_at field uses October 27 midnight Eastern as a date-only reporting placeholder, not a verified execution timestamp. CATALYST: Moderna and Merck reported positive late-stage results for personalized melanoma vaccine intismeran combined with Keytruda. Reuters reported a 42% reduction in the risk of cancer recurrence or death and a 38% reduction in distant metastasis or death versus Keytruda alone. These are meaningful clinical findings, but William Blair believes Moderna's valuation already reflects substantial success beyond melanoma. The downgrade therefore concerns the valuation assigned to genuine clinical progress rather than evidence that the melanoma trial failed. Future efficacy in other tumor types remains uncertain. Sources: https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-sheds-about-24-billion-cancer-vaccine-data-triggers-sell-the-news-2026-10-22/ and https://www.benzinga.com/trading-ideas/movers/26/10/62618658/william-blair-takes-a-shot-at-moderna-stock-downgrade-to-market-perform-after-a-545-run. PRE-EVENT PRICE PATH: Moderna closed at $245.81 on October 21 before a major October 22 selloff, during which the shares reached $180.80 and closed at $202.63. October 22 volume was 49.95 million shares, approximately 2.49 times the completed-session 20-day average. This supports a substantial repricing but does not distinguish informed selling from temporary capitulation. The next two completed sessions closed at $200.10 and $198.85, respectively. The stock remained far below its October 21 closing level before the newly reported downgrade. OBSERVED REACTION: Using October 27 as the action's reported date, the previous completed regular-session close of $198.85 at 2026-10-26T16:00:00-04:00 is the available reference; source=https://stockanalysis.com/stocks/mrna/history/. Because reporting conflicts over the exact issuance date, this is a pre-report reference rather than independently verified pricing immediately before the original research note. Latest_price=194.31 USD; quote_time=2026-10-27T10:47:00-04:00; quote_type=regular-session, provider-labelled real-time; source=https://stockanalysis.com/stocks/mrna/history/. The observed October 26-close-to-quote change is -2.28%, but a pure analyst-event return cannot be isolated. October 27 PARTIAL SESSION, as of 10:47 EDT: open=192.23, high_so_far=194.30, low_so_far=179.53, cumulative_volume=7047318 shares. The quote is approximately at the displayed high, subject to one-cent rounding or asynchronous display differences, and represents a substantial recovery from the intraday low. This is powerful counter-evidence to immediate bearish continuation. Relative intraday volume cannot be established without a comparable same-time historical baseline. COMPLETED DAILY OHLCV: US Eastern regular sessions, 09:30-16:00 EDT. Fields are session_date, open, high, low, close, volume in shares. Split-adjusted OHLC, excluding dividend adjustment and the unfinished October 27 bar. 2026-10-20: 226.03, 243.98, 216.65, 242.08, 16858882 2026-10-21: 242.20, 254.48, 239.55, 245.81, 16009396 2026-10-22: 240.13, 241.26, 180.80, 202.63, 49947211 2026-10-23: 196.69, 206.97, 183.00, 200.10, 21566921 2026-10-26: 186.90, 203.82, 181.65, 198.85, 17108669 return_5d_pct=-12.36; calculation uses October 19 close=226.89 and October 26 close=198.85. high_20d=254.48; low_20d=180.80; avg_volume_20d=20031738.0 shares; avg_dollar_volume_20d_usd=4202160822. Historical source: https://stockanalysis.com/stocks/mrna/history/. THESIS: The highly volatile October 22 decline and failure to recover toward the earlier $245-$255 region are consistent with investors reducing the valuation premium after the clinical results. William Blair's downgrade adds a valuation-based reason for further caution. The October 22 lower wick and today's sharp recovery from $179.53 indicate aggressive buying interest at depressed levels, however, and represent the strongest observed counter-evidence. The successful melanoma data are fundamentally constructive even if the stock's valuation remains demanding. A sustained recovery above $203.82, October 26's high, followed by strength above $206.97, October 23's high, would invalidate the immediate bearish-continuation thesis. New information indicating broader commercial effectiveness could also reverse the valuation argument. The call is for another 1.8% decline from submission, with reduced confidence due to the intraday recovery and uncertainty about the original note's issuance time.
   William Blair (Myles Minter) downgraded to Market Perform on 2026-10-27 — source
   Return: 12.75%; alpha: -12.99%.
5. ABT — confidence 62%. ANALYST ACTION: Argus Research analyst David Round downgraded Abbott Laboratories from Buy to Hold. No new target was verified, so previous_target and new_target are omitted. The action was reported October 27; the exact original research-note publication time was not established, so published_at uses midnight Eastern as a date-only placeholder. CATALYST: Argus highlighted Abbott's reduced 2026 sales-growth guidance, reimbursement uncertainty, competitive pressure and uncertainty surrounding the planned separation of its Nutrition business. These concerns are connected to business fundamentals and expected execution rather than merely a change in market mood. The firm's positive long-term assessment of the planned separation is important counter-evidence: the spin-off could ultimately result in a faster-growing, higher-margin company. Source: https://www.tipranks.com/news/the-fly/abbott-cut-to-hold-at-argus-amid-reimbursement-uncertainty-competitive-pressure-thefly-news. PRE-EVENT PRICE PATH: Abbott experienced a volatile October 21 session, falling to $97.67 despite reaching $106.35 intraday, then recovered over the following three completed sessions. The October 22, 23 and 26 closes were $102.51, $103.70 and $104.88. October 26 closed in the upper portion of its daily range, suggesting that buyers had been regaining control. The October 21 session's 22.91 million shares were approximately 2.26 times its 20-day average, consistent with substantial activity around the earlier repricing, although volume alone does not establish the motive. OBSERVED REACTION: The verified pre-event quote is the October 26 regular-session close=$104.88 at 2026-10-26T16:00:00-04:00, source=https://stockanalysis.com/stocks/abt/history/. Latest_price=103.49 USD; quote_time=2026-10-27T10:47:00-04:00; quote_type=regular-session, provider-labelled real-time; source=https://stockanalysis.com/stocks/abt/history/. The observed pre-event-close-to-quote change is -1.33%. October 27 PARTIAL SESSION, as of 10:47 EDT: open=102.81, high_so_far=103.86, low_so_far=101.91, cumulative_volume=1279661 shares. Today's initial weakness has partially recovered, since the quote is above the opening price. This rebound weakens a straightforward bearish continuation argument. Same-time relative intraday volume is unavailable and cannot be established from the partial volume alone. COMPLETED DAILY OHLCV: US Eastern regular sessions, 09:30-16:00 EDT. Fields are session_date, open, high, low, close, volume in shares. Split-adjusted OHLC, not dividend-adjusted Adj Close, excluding the unfinished October 27 session. 2026-10-20: 105.53, 105.62, 100.75, 102.45, 13854369 2026-10-21: 101.31, 106.35, 97.67, 100.51, 22909735 2026-10-22: 101.50, 102.90, 99.91, 102.51, 10661558 2026-10-23: 102.28, 104.00, 101.56, 103.70, 10296890 2026-10-26: 103.01, 105.24, 102.90, 104.88, 7842175 return_5d_pct=0.79; calculation uses October 19 close=104.06 and October 26 close=104.88. high_20d=106.35; low_20d=95.06; avg_volume_20d=10147384.5 shares; avg_dollar_volume_20d_usd=1026048528. Historical source: https://stockanalysis.com/stocks/abt/history/. THESIS: The Argus downgrade provides an additional reason to question the recent recovery, particularly because the company has already lowered its sales-growth outlook. The October 27 gap lower suggests investors are reassessing the preceding rebound. However, the strongest counter-evidence is Abbott's three-session recovery through October 26, together with today's recovery from the partial-session low. Its previous completed-session close was also near the top of its daily range, supporting the possibility that existing fundamental concerns have already been priced in. A sustained recovery above $105.24, the October 26 high, would invalidate the immediate bearish thesis; a move beyond the 20-day high of $106.35 would provide stronger contrary evidence. Improving reimbursement clarity or positive developments concerning the Nutrition separation could reverse the sentiment. Because Abbott's price action has been less directional than that of the other selections, the expected incremental decline is limited to 0.7%, excluding the already observed 1.33% decline.
   Argus Research (David Round) downgraded to Hold on 2026-10-27 — source
   Return: 0.43%; alpha: -0.66%.

Full prediction and audit record

DeepSeek

Scoring window: Oct 27, 10:56 AM EDT → Oct 28, 10:56 AM EDT.

View full picks and reasoning

One-session US equity view: AI and semiconductor leadership remains intact after Anthropic's IPO filing, while software and defense show stock-specific dispersion. I expect upgrade-driven momentum to continue in TSLA, AVGO and LITE, continued selling pressure in HUBS after its UBS downgrade, and a post-upgrade pause in LMT after its large one-day rerating.

1. TSLA — confidence 65%. Barclays upgraded TSLA to Overweight from Equal Weight and raised its price target to $450 from $370 before the Oct. 26 open, citing a potential SpaceX merger, a stronger core auto/energy outlook and Robotaxi inflection; analyst Dan Levy. Fact: the rating and target change. Inference: the SpaceX merger is optionality rather than a completed deal. Pre-event Oct. 23 close was $372.22; TSLA closed Oct. 26 at $391.62 (+5.21%) and traded $401.905 at 10:11 ET Oct. 27 (+2.63% on the day), so the observed event-to-quote move is about +7.98%. Five completed daily bars, oldest to newest: 2026-10-20 O370.28 H377.59 L363.64 C373.71 V30,590,704; 2026-10-21 O381.43 H388.84 L380.51 C386.47 V43,161,811; 2026-10-22 O374.29 H388.86 L373.71 C374.58 V51,059,477; 2026-10-23 O373.20 H377.32 L365.27 C372.22 V34,682,894; 2026-10-26 O383.83 H397.27 L383.73 C391.62 V54,072,466. return_5d_pct = 6.40%; high_20d = 397.27; low_20d = 345.88; avg_volume_20d = 36,590,365. Partial Oct. 27 session: open 398.00, high 404.00, low 395.25, cumulative volume 13.02M, latest $401.905 at 10:11 ET, regular-session live/delayed vendor quote. Strongest counter-evidence: Q3 EPS fell 43.6% year over year and the stock is extended above its 20-day range; the upgrade also leans on merger speculation. Price/volume supports continuation, but a close below $391.62 or a failed hold of $400 would invalidate the up thesis. The pre-event-to-quote move is already elapsed; the call is for continued drift over the remaining window, not a repeat of the full reaction.
   Barclays (Dan Levy) upgraded to Overweight, target $450 (from $370) on 2026-10-26 — source
   Return: -0.55%; alpha: -0.78%.
2. AVGO — confidence 62%. DA Davidson upgraded AVGO to Buy from Neutral and raised its target to $400 from $350 on Oct. 27, citing Anthropic's IPO filing and evidence the AI spending cycle is not over; analyst Gil Luria. Fact: the upgrade and target increase. Inference: this is a confidence/sentiment catalyst tied to customer capex, not a change in reported Broadcom fundamentals. Pre-event Oct. 26 close was $329.17; AVGO traded $339.90 at 10:02 ET Oct. 27 (+3.26%), so the observed event-to-quote move is +3.26%. Five completed daily bars, oldest to newest: 2026-10-20 O334.00 H341.10 L330.80 C334.37 V15,951,817; 2026-10-21 O338.03 H339.24 L332.29 C337.80 V17,123,631; 2026-10-22 O326.53 H330.82 L321.02 C323.24 V28,139,147; 2026-10-23 O321.50 H327.70 L320.23 C321.68 V15,917,005; 2026-10-26 O324.53 H332.12 L323.25 C329.17 V18,785,987. return_5d_pct = -1.62%; high_20d = 380.84; low_20d = 320.23; avg_volume_20d = 21,545,712. Partial Oct. 27 session: open 339.34, high 345.67, low 337.40, cumulative volume 5.10M, latest $339.90 at 10:02 ET, regular-session live/delayed vendor quote. Strongest counter-evidence: AVGO remains well below its 20-day high of $380.84 and the upgrade gap could fade if the broad chip rally stalls. Price/volume supports continuation while the stock holds above the Oct. 26 close of $329.17 and the session low of $337.40; a loss of $329.17 would invalidate the up call. The pre-event-to-quote gain is already observed; the remaining call is for follow-through, not the initial gap.
   DA Davidson (Gil Luria) upgraded to Buy, target $400 (from $350) on 2026-10-27 — source
   Return: 1.45%; alpha: 1.21%.
3. HUBS — confidence 60%. UBS downgraded HUBS to Neutral from Buy while raising its target to $310 from $290 on Oct. 27, citing uneven small-business and new-logo demand, nascent AI monetization, intensifying down-market competition and potential go-to-market friction from the pricing transition; analyst Taylor McGinnis. Fact: the downgrade. Inference: the higher target limits absolute downside, but the removal of a Buy rating weakens near-term support after a more-than-30% one-month rally. Pre-event Oct. 26 close was $263.99; the latest verifiable quote is $259.91 premarket at 05:17:10 ET Oct. 27 (-1.55%), and no regular-session quote was verified, so freshness is stale relative to answering time. Five completed daily bars, oldest to newest: 2026-10-20 O240.01 H252.32 L239.57 C250.76 V1,147,145; 2026-10-21 O250.41 H254.90 L247.00 C249.90 V639,194; 2026-10-22 O253.80 H268.60 L253.42 C267.19 V1,364,456; 2026-10-23 O267.52 H271.54 L262.27 C270.88 V874,176; 2026-10-26 O270.88 H271.60 L257.89 C263.99 V822,967. return_5d_pct = 5.28%; high_20d = 271.60; low_20d = 194.27; avg_volume_20d = 1,141,547. Counter-evidence: HUBS is still above its rising 20-day low and the $310 target sits above the market, so selling may be contained. A regular-session reclaim above $263.99 or $271.60 would invalidate the down call. The premarket decline is already observed; the remaining thesis is additional weakness during the scored window, not the premarket move itself.
   UBS (Taylor McGinnis) downgraded to Neutral, target $310 (from $290) on 2026-10-27 — source
   Return: -0.58%; alpha: 0.35%.
4. LITE — confidence 58%. StoneX initiated coverage of LITE with a Buy rating and a $1,200 price target on Oct. 26 at 14:02 ET, citing critical positions in high-speed InP lasers, optical transceivers and optical switching, with AI-related optoelectronic capacity effectively committed into early 2029; analyst Cody Acree. Fact: the initiation. Inference: the target implies large upside, but the stock has already re-rated sharply and remains below its October high. Pre-event price was about $781.32 at 14:02; LITE closed Oct. 26 at $818.10 (+8.19%) and traded $838.37 at 10:17 ET Oct. 27 (+2.48%), an observed event-to-quote move of roughly +7.3%. Five completed daily bars, oldest to newest: 2026-10-20 O816.58 H837.78 L785.00 C822.51 V4,526,943; 2026-10-21 O863.14 H878.90 L826.01 C850.70 V3,747,633; 2026-10-22 O804.06 H811.00 L746.23 C752.54 V6,157,252; 2026-10-23 O760.00 H788.90 L736.01 C756.17 V3,934,967; 2026-10-26 O766.32 H840.47 L756.00 C818.10 V6,081,697. return_5d_pct = -1.97%; high_20d = 1143.00; low_20d = 736.01; avg_volume_20d = 4,986,953. Partial Oct. 27 session: open 841.94, high 847.264, low 820.30, cumulative volume 1.25M, latest $838.37 at 10:17 ET, regular-session live/delayed vendor quote. Strongest counter-evidence: LITE is still about 27% below its Oct. 9 high and the initiation-day gain could exhaust; the stock also trades at a rich valuation with negative trailing earnings. Price/volume supports continuation while it holds above the Oct. 26 close of $818.10 and the session low of $820.30; a loss of $818.10 would invalidate the up call.
   StoneX (Cody Acree) initiated coverage to Buy, target $1200 on 2026-10-26 — source
   Return: 3.77%; alpha: 3.54%.
5. LMT — confidence 55%. Morgan Stanley upgraded LMT to Overweight from Equal Weight and raised its target to $835 from $690 on Oct. 26 at 05:35 ET, citing a 10-year F-35 framework agreement that removes a major risk and a missile-production ramp; analyst Kristine Liwag. Fact: the upgrade and target increase. Inference: much of that de-risking was already reflected in the prior two sessions' roughly 9.5% rally, and the stock is now stalling below its Oct. 26 high. Pre-event Oct. 23 close was $604.18; LMT closed Oct. 26 at $635.20 (+5.13%) and traded $631.29 at 10:17 ET Oct. 27 (-0.62%), an observed event-to-quote move of about +4.49% but now below the Oct. 26 close. Five completed daily bars, oldest to newest: 2026-10-20 O553.00 H559.48 L545.73 C548.71 V1,471,572; 2026-10-21 O547.14 H552.82 L544.66 C551.51 V1,470,303; 2026-10-22 O579.51 H608.00 L577.24 C589.91 V2,960,356; 2026-10-23 O584.20 H609.32 L580.00 C604.18 V1,817,433; 2026-10-26 O613.37 H636.56 L611.27 C635.20 V2,669,305. return_5d_pct = 15.76%; high_20d = 636.56; low_20d = 497.00; avg_volume_20d = 1,347,694. Partial Oct. 27 session: open 626.91, high 633.56, low 626.01, cumulative volume 398,300, latest $631.29 at 10:17 ET, regular-session live/delayed vendor quote. Strongest counter-evidence: the $835 target is far above the market, defense demand is strong and a shallow pullback may be bought. A reclaim above $636.56 or $635.20 would negate the fade call. Price/volume shows a post-upgrade stall, supporting a one-session pause rather than a trend reversal.
   Morgan Stanley (Kristine Liwag) upgraded to Overweight, target $835 (from $690) on 2026-10-26 — source
   Return: -0.54%; alpha: 0.30%.

Full prediction and audit record

How models have done in Analyst Revisions

ForecastNest's own settled Analyst Revisions runs at this horizon, up to and including this one. Members' own research is not counted. Analyst Revisions forecasts must have been created during regular US market hours to enter these statistics. Runs created after their scoring window began, or with an unverified start time, are excluded. The chart is the average alpha vs SPY per run. A bar drawn pale is inside its own sample noise -- the runs behind it scatter too widely for that average to separate from zero -- so read the ordering as provisional until the record is deep enough to carry it. The table below adds how many of the five picks beat SPY, which is a steadier measure on a short record because it counts several picks a run rather than one result.

Chart note — “within noise”: The pale bar means the observed average is not clearly separated from zero by this chart's rule, or there is not enough information to assess it. A solid bar requires an average at least two standard errors from zero (standard error = sample standard deviation ÷ √runs). Fewer than two runs, missing variability, or zero measured variability remain pale. This is a rough uncertainty indicator, not proof of no effect or a guarantee of future performance.

Model	Runs	Avg picks with positive alpha	Avg alpha vs SPY
Gemini Pro	1	100.00%	+0.74%
Grok 4.5	8	55.00%	+0.57%
GPT-6	13	49.23%	+0.20%
Gemini 3.6 Flash High	1	60.00%	+0.14%
DeepSeek	13	52.31%	+0.00%
Perplexity	10	46.00%	-0.15%
Muse Spark 1.1	13	52.31%	-0.19%
Gemini 3 Pro	7	42.86%	-0.20%
Gemini 2.5 Flash	2	40.00%	-0.21%
Claude Sonnet 4.6	1	80.00%	-0.32%
Claude Opus 5.5	3	40.00%	-0.71%
Grok 4	2	20.00%	-0.72%
Claude Sonnet 5.5	3	53.33%	-0.92%
Grok 4.7	3	40.00%	-1.14%
Gemini 1.5 Pro	2	50.00%	-1.26%

View settlement prices

Model	Symbol	Start	End	Source	Notes
Perplexity	SPY	767.92	770.42	https://finance.yahoo.com/quote/SPY/history/
Perplexity	TSLA	402.4	399.7069	https://finance.yahoo.com/quote/TSLA/history/
Perplexity	LMT	625.96	623.99	https://finance.yahoo.com/quote/LMT/history/
Perplexity	MELI	1709.805	1660.155	https://finance.yahoo.com/quote/MELI/history/
Perplexity	AVGO	339.005	345.76	https://finance.yahoo.com/quote/AVGO/history/
Perplexity	AAPL	346.0469	344.875	https://finance.yahoo.com/quote/AAPL/history/
Gemini 2.5 Flash	SPY	767.92	770.42	https://finance.yahoo.com/quote/SPY/history/
Gemini 2.5 Flash	FICO	695.81	699.95	https://finance.yahoo.com/quote/FICO/history/
Gemini 2.5 Flash	LKQ	17.48	17.14	https://finance.yahoo.com/quote/LKQ/history/
Gemini 2.5 Flash	XP	15.89	15.58	https://finance.yahoo.com/quote/XP/history/
Gemini 2.5 Flash	DY	231.15	230.525	https://finance.yahoo.com/quote/DY/history/
Gemini 2.5 Flash	AAOI	75.1355	78.085	https://finance.yahoo.com/quote/AAOI/history/
Grok 4.7	SPY	767.8	770.2599	https://finance.yahoo.com/quote/SPY/history/
Grok 4.7	AVGO	338.91	345.53	https://finance.yahoo.com/quote/AVGO/history/
Grok 4.7	MELI	1708.02	1660.35	https://finance.yahoo.com/quote/MELI/history/
Grok 4.7	MTSI	252.52	255.535	https://finance.yahoo.com/quote/MTSI/history/
Grok 4.7	HUBS	254	252.695	https://finance.yahoo.com/quote/HUBS/history/
Grok 4.7	MRNA	194.69	216.295	https://finance.yahoo.com/quote/MRNA/history/
Claude Sonnet 5.5	SPY	767.82	770.1875	https://finance.yahoo.com/quote/SPY/history/
Claude Sonnet 5.5	AVGO	338.885	345.09	https://finance.yahoo.com/quote/AVGO/history/
Claude Sonnet 5.5	HUBS	253.65	252.695	https://finance.yahoo.com/quote/HUBS/history/
Claude Sonnet 5.5	MRNA	194.0876	216.755	https://finance.yahoo.com/quote/MRNA/history/
Claude Sonnet 5.5	XYZ	74.5	74.4	https://finance.yahoo.com/quote/XYZ/history/
Claude Sonnet 5.5	TSLA	401.97	400.055	https://finance.yahoo.com/quote/TSLA/history/
Muse Spark 1.1	SPY	768.33	770.23	https://finance.yahoo.com/quote/SPY/history/
Muse Spark 1.1	AVGO	339.475	345.055	https://finance.yahoo.com/quote/AVGO/history/
Muse Spark 1.1	CDNS	334.37	344.62	https://finance.yahoo.com/quote/CDNS/history/
Muse Spark 1.1	R	281.19	276.71	https://finance.yahoo.com/quote/R/history/
Muse Spark 1.1	XYZ	74.625	74.49	https://finance.yahoo.com/quote/XYZ/history/
Muse Spark 1.1	HUBS	254.12	252.9	https://finance.yahoo.com/quote/HUBS/history/
GPT-6	SPY	768.405	770.2	https://finance.yahoo.com/quote/SPY/history/
GPT-6	AVGO	340.01	344.93	https://finance.yahoo.com/quote/AVGO/history/
GPT-6	TSLA	402.43	400.22	https://finance.yahoo.com/quote/TSLA/history/
GPT-6	HUBS	254.5	253.02	https://finance.yahoo.com/quote/HUBS/history/
GPT-6	MRNA	192.6768	217.25	https://finance.yahoo.com/quote/MRNA/history/
GPT-6	ABT	103.27	103.71	https://finance.yahoo.com/quote/ABT/history/
DeepSeek	SPY	768.405	770.2	https://finance.yahoo.com/quote/SPY/history/
DeepSeek	TSLA	402.43	400.22	https://finance.yahoo.com/quote/TSLA/history/
DeepSeek	AVGO	340.01	344.93	https://finance.yahoo.com/quote/AVGO/history/
DeepSeek	HUBS	254.5	253.02	https://finance.yahoo.com/quote/HUBS/history/
DeepSeek	LITE	854.8414	887.11	https://finance.yahoo.com/quote/LITE/history/
DeepSeek	LMT	626.875	623.51	https://finance.yahoo.com/quote/LMT/history/

Standard prompt analyst-revision-v3, SHA-256 0d175b532089b90929a20b879346535f5d782ae992a6ffd030bb4af485a18613. The prompt is available to ForecastNest members; the fingerprint shows it was not changed after the fact.

Calculation: analyst-revision-submission-v1.